This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

31 Oct 2013

Testing Generic Inhaled Products…

Mark Copley, Sales Director for Copley Scientific, will discuss optimal testing strategies for the development of inhaled generic products at a specialist meeting in London, UK, in November.

His invited presentation on 5 November 2013 is part of a pre-conference workshop on Bioequivalence for Inhaled Products, taking place ahead of the Management Forum Inhaled Drug Delivery (IDD) conference on 6 November. Both are being held at The Rembrandt Hotel, London.

The pre-conference workshop and the full conference programme include presentations from a number of leading industrialists and will cover current trends in inhaled drug delivery technology and regulation. To register for the workshop, or to find out more, click here.

Mark Copley’s presentation ‘Methodologies for in vitro bioequivalence testing of generic inhaled products’, will examine the laboratory tests that can be used to demonstrate that a generic product delivers equivalent clinical efficacy to a reference labelled drug. Generic inhaled drug development is a fast-growing area of the pharmaceutical industry. A primary focus is the commercialisation of inexpensive, efficient products for treating asthma and chronic obstructive pulmonary disease (COPD).  Demonstrating bioequivalence through in vitro testing minimises the need for clinical trials, accelerating time to market and reducing development costs. Mark Copley will review the regulatory framework in this area and outline efficient testing strategies designed to fulfil the associated requirements.

Related News